<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171203037733N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-15</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Effect of pippermint on nausea in pediatrics with leukemia undergoing chemotherapy</public_title>
      <acronym></acronym>
      <scientific_title>Effect of Peppermint (Mentha piperita) on Nausea, Vomiting and Anorexia in pediatrics with leukemia Undergoing Chemotherapy: A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54426</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Samples are available from among children with acute myeloid leukemia and lymphocytosis undergoing chemotherapy. The samples are then assigned to two random groups as random quadruple blocks A, A, B, and B.It should be noted that the Rand function in Excel software will be used for randomization.
The statistician and the sample collector are not aware of how the samples are blinded, Blinding description: The statistician will do the randomization, one of the colleagues will do the sampling plan, and the treating physician will assign the patients to the groups.
The statistician and the sample collector are not aware of how the samples are blinded.</study_design>
      <phase>3</phase>
      <hc_freetext>Nausea, vomiting and Anorexia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The samples are assigned to two random groups as quadruple random blocks A, A, B, and B. First, written and informed consent was obtained from the patients. Then, with the help of VAS visual scale, the amount of nausea and anorexia and with the help of frequency table, the number of vomiting cases in the day before chemotherapy in the intervention and control groups are examined. In the intervention group, in addition to routine anti-nausea treatments, 12 hours before chemotherapy and up to 48 hours after, 1 drop in weight (1 Drop per kilogram) every 8 hours, peppermint extract (Super Mate drops) (Barij Essence Pharmaceutical Company) with 20 cc Urban tap water is given to patients (measurement of nausea, vomiting and anorexia half an hour before chemotherapy, immediately, 24 and 48 hours after chemotherapy) .All medications taken are recorded by the sample collector. Intervention 2: Control group: In the control group, they receive only routine anti-nausea drugs and their nausea, vomiting and anorexia are measured by VAS scale half an hour before chemotherapy, immediately, 24 and 48 hours after re-chemotherapy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no final decision to publish yet.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehran Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Postal Code: 38817-43364, Azadi St., Khomein School of Medical Sciences, Khomein, Iran</address>
        <city>khomein</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>38817-43364</zip>
        <telephone>+98 86 4622 1534</telephone>
        <email>mehranakbari1373@yahoo.com</email>
        <affiliation>Khomein University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehran Ahbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadi St., Khomein School of Medical Sciences, Khomein, Iran</address>
        <city>Khomein</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>38817-43364</zip>
        <telephone>+98 86 4622 1534</telephone>
        <email>mehranakbari1373@yahoo.com</email>
        <affiliation>Khomein University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Written conset to participate in the study
Definitive diagnosis of myeloid leukemia and  acute lymphocytic (ALL and AML) by a pediatric hematologist and oncologist (other than None M3ALL )
Receiving chemotherapy courses
History of receiving at least one course of chemotherapy
Experience of nausea following previous chemotherapy sessions
No concomitant radiotherapy with chemotherapy
Age 3 to 18 years</inclusion_criteria>
      <agemin>3 years</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Using medications or other treatments to reduce nausea other than the usual prescribed anti-nausea and vomiting medications (especially herbal remedies)
Nausea and vomiting resistant to treatment
Unwillingness to participating in the study
sensitivity to mint
other nausea problems such as hypertention , liver failure , kidney and digestive problems</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Nausea and vomiting</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The samples are assigned to two random groups as quadruple random blocks A, A, B, and B. First, written and informed consent was obtained from the patients. Then, with the help of VAS visual scale, the amount of nausea and anorexia and with the help of frequency table, the number of vomiting cases in the day before chemotherapy in the intervention and control groups are examined. In the intervention group, in addition to routine anti-nausea treatments, 12 hours before chemotherapy and up to 48 hours after, 1 drop in weight (1 Drop per kilogram) every 8 hours, peppermint extract (Super Mate drops) (Barij Essence Pharmaceutical Company) with 20 cc Urban tap water is given to patients (measurement of nausea, vomiting and anorexia half an hour before chemotherapy, immediately, 24 and 48 hours after chemotherapy) .All medications taken are recorded by the sample collector.</i_keyword>
      <i_keyword>Control group: In the control group, they receive only routine anti-nausea drugs and their nausea, vomiting and anorexia are measured by VAS scale half an hour before chemotherapy, immediately, 24 and 48 hours after re-chemotherapy.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nausea. Timepoint: Before, immediately, 24 hours, 48 hours after chemotherapy. Method of measurement: VAS questionnaire and measurement table and Face scale.</prim_outcome>
      <prim_outcome>Vomiting. Timepoint: Before, immediately, 24 hours, 48 hours after chemotherapy. Method of measurement: VAS questionnaire and measurement table and Face scale.</prim_outcome>
      <prim_outcome>Anorexia. Timepoint: Before, immediately, 24 hours, 48 hours after chemotherapy. Method of measurement: VAS questionnaire and measurement table and Face scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-08</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Arak Univerity of Medical Sciences, Payambar aazam, University Complex, Basij SQ, Sardasht region Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
